glp-1 without diabetes Receptor Agonists and Research to Treat Overeating and Substance Use Disorders GLP-1 agonists and changes in

In a review of racial and ethnic differences in obesity outcomes of lifestyle, surgical, and pharmacological interventions published between 2000 and 2022, lower efficacy of lifestyle and surgical interventions was commonly identified among Black compared with White participants (with no or smaller differences for Hispanic compared with White participants)

With regard to adverse effects, gastrointestinal intoleranceespecially nausea and vomitingrepresents the class-defining limitation

Always consult a qualified provider from BodyLogicMD before starting any new medication or treatment regimen.

Improves blood sugar control and reduces cardiovascular risk

N Engl J Med 2015;373:2117-28.ArticlePubMed 37

doi: 10.1111/apt.12092